Amgen forced to suspend trial of promising cancer drug
Amgen Inc., a unit of Takeda Pharmaceutical Co. has been forced to suspend a late-stage trial of a very promising cancer drug.
Amgen Inc. today announced that the FDA has accepted Amgen's submission and filed a Biologics License Application for denosumab, an investigational RANK Ligand inhibitor